2상모집 중
Pembrolizumab in Locally Advanced Sinonasal Carcinoma
연구 개요
This study will test the Safety and activity of pembrolizumab plus chemotherapy as neoadjuvant treatment in locally advanced sinonasal undifferentiated carcinoma (SNUC). Activity of neoadjuvant chemotherapy in locally advanced SNUC has been already demonstrated; the primary hypothesis is that the addition of pembrolizumab as neoadjuvant and adjuvant agent might confirm the results obtained with a combined treatment strategy including chemotherapy, decreasing the burden of treatment-related side effects.
- 스폰서
- 협력: 머크(MSD)
- 적응증
- Sinonasal Undifferentiated Carcinoma
- 중재
- Pembrolizumab, Cisplatin, Docetaxel, Carboplatin
- 목표 등록
- 28명
- 시작일
- 2024-12-24
- 완료(예정)
- 2027-12-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.